NCT00398138View on ClinicalTrials.gov

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
LeukemiaLung CancerMalignant MesotheliomaMyelodysplastic SyndromesPrimary Peritoneal Cavity Cancer
Interventions
BIOLOGICAL

WT-1 analog peptide vaccine

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

sargramostim

GENETIC

polymerase chain reaction

OTHER

flow cytometry

OTHER

immunoenzyme technique

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Innovive Pharmaceuticals
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Innovive Pharmaceuticals

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER